S-1: Palatin Technologies Eyes $25 Million Capital Raise Through Stock and Warrant Offering

Palatin Technologies is seeking to raise capital through a public offering of common stock and warrants, aiming to bolster working capital and fund ongoing development programs.

Summary

• Palatin Technologies has filed a registration statement for a proposed public offering.
• The offering includes up to 17,317,816 shares of common stock and accompanying Series F common stock purchase warrants.
• Pre-funded warrants may be offered in lieu of common stock to certain purchasers.
• The assumed combined public offering price is $0.7218 per share of common stock and accompanying common warrant, based on the closing price on March 26, 2025.
• The company intends to use the net proceeds primarily for working capital and general corporate purposes, including development work on its combination of bremelanotide and tirzepatide.
• The offering is being conducted on a reasonable best efforts basis with A.G.P./Alliance Global Partners and Laidlaw & Company (UK) Ltd. acting as placement agents.
• The offering is expected to terminate on April 25, 2025, unless terminated earlier.
• The company is currently not in compliance with NYSE American continued listing standards and is subject to delisting procedures if compliance is not regained by April 10, 2025.

Sentiment

Score: 5

Explanation: Neutral. The document outlines a financing plan with both potential benefits and risks. The company's financial situation and compliance issues temper the positive aspects of the capital raise.

Positives

• The offering could provide Palatin Technologies with significant capital to advance its development programs.
• The use of pre-funded warrants offers flexibility for investors with beneficial ownership limitations.
• The company has engaged experienced placement agents to manage the offering.
• The company intends to use the net proceeds primarily for working capital and general corporate purposes, including for development work on our combination of bremelanotide, or another melanocortin-4 agonist, and tirzepatide, a GLP-1 agonist.

Negatives

• The offering is on a best efforts basis, so there is no guarantee that the company will raise the full amount.
• The company is not currently in compliance with NYSE American continued listing standards, raising concerns about potential delisting.
• The company has a history of substantial net losses, including a net loss of $29.7 million for the year ended June 30, 2024.
• The company expects to incur substantial net losses over the next few years, and may never achieve or maintain profitability.

Risks

• The company's ability to raise sufficient capital is uncertain.
• Failure to regain compliance with NYSE American listing standards could lead to delisting.
• The company's history of net losses raises concerns about its long-term financial viability.
• The company may need to curtail operations significantly, cease clinical trials, and decrease staffing levels if it is unable to raise sufficient additional funds when needed.
• The company may seek to license, sell or otherwise dispose of our product candidates, technologies and contractual rights on the best possible terms available. Even if we are able to license, sell or otherwise dispose of our product candidates, technologies and contractual rights, it is likely to be on unfavorable terms and for less value than if we had the financial resources to develop or otherwise advance our product candidates, technologies and contractual rights ourselves.

Future Outlook

The company intends to use the net proceeds from this offering primarily for working capital and general corporate purposes, including for development work on our combination of bremelanotide, or another melanocortin-4 agonist, and tirzepatide, a GLP-1 agonist.

Industry Context

The announcement reflects a common strategy for biopharmaceutical companies to raise capital for research and development, especially for companies with ongoing clinical trials and the need to fund operations.

Comparison to Industry Standards

• The terms of the warrants, including the exercise price and expiration date, are typical for similar offerings in the biopharmaceutical industry.
• The placement agent fees are within the range of customary fees for best efforts offerings.
• The use of pre-funded warrants is a common strategy to accommodate investors with beneficial ownership limitations, similar to practices seen in other small-cap biotech offerings.

Legal Proceedings

• On February 13, 2025, a complaint was filed in the Supreme Court of the State of New York, County of New York, captioned H.C. Wainwright & Co., LLC (Wainwright) v. Palatin Technologies, Inc., Case No: 650878/2025.
• The complaint names the Company as defendant, asserting three causes of action for breach of contract and seeking monetary damages and the award of warrants allegedly due under the parties agreement.
• On March 20, 2025, the Company filed its answer in response to the complaint, in which it denied all liability and asserted several affirmative defenses.
• The Company plans to vigorously defend against the lawsuit and the action will proceed next to the discovery stage and for further proceedings.

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• The offering could provide the company with the resources to advance its development programs, potentially benefiting shareholders in the long term.
• Employees may benefit from the company's increased financial stability.
• Customers may benefit from the development of new products.

Next Steps

• The company will need to secure commitments from investors to purchase the securities.
• The company will need to file the final prospectus with the SEC.
• The company will need to regain compliance with NYSE American listing standards.
• The company will need to complete the closing of the offering.

Key Dates

Keywords

public offering, common stock, warrants, pre-funded warrants, capital raise, Palatin Technologies, A.G.P./Alliance Global Partners, Laidlaw & Company, biopharmaceutical, bremelanotide, tirzepatide